drugset / Trial / NCT03159078

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

NCT03159078

Phase 3 Unknown 40 enrolled University of Puerto Rico
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram negative infections. The investigators intend to evaluate if this synergistic drug regimen correlates with improved outcomes against gram-negative infections in critically ill patients including: better clinical resolution, reduced length of stay at hospital, reduced length of stay at the intensive care unit, and less recurrence of infection.

Timeline

Start
2017-05-25
Primary completion
2019-12-01
Completion
2019-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Polymyxin B Peptide Intravenous

Indications

No indication recorded.